Chardan Capital maintains Ocular Therapeutix Buy and $23 price target
Chardan Capital maintained its Buy rating on Ocular Therapeutix and kept a $23.00/share price target,
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.